NO317800B1 - Rekombinante DNA-molekyler som koder for benmorfogene proteiner og rensede sammensetninger og fremgangsmater derav. - Google Patents
Rekombinante DNA-molekyler som koder for benmorfogene proteiner og rensede sammensetninger og fremgangsmater derav. Download PDFInfo
- Publication number
- NO317800B1 NO317800B1 NO19962303A NO962303A NO317800B1 NO 317800 B1 NO317800 B1 NO 317800B1 NO 19962303 A NO19962303 A NO 19962303A NO 962303 A NO962303 A NO 962303A NO 317800 B1 NO317800 B1 NO 317800B1
- Authority
- NO
- Norway
- Prior art keywords
- bmp
- amino acid
- seq
- refolding
- replaced
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 89
- 102000004169 proteins and genes Human genes 0.000 title claims description 84
- 238000000034 method Methods 0.000 title claims description 46
- 239000000203 mixture Substances 0.000 title claims description 29
- 108020004511 Recombinant DNA Proteins 0.000 title claims description 11
- 210000000988 bone and bone Anatomy 0.000 title description 30
- 230000000921 morphogenic effect Effects 0.000 title description 24
- 238000004519 manufacturing process Methods 0.000 claims abstract description 19
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims abstract description 16
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims abstract description 16
- 229940112869 bone morphogenetic protein Drugs 0.000 claims abstract description 16
- 235000018102 proteins Nutrition 0.000 claims description 82
- 125000003729 nucleotide group Chemical group 0.000 claims description 55
- 239000002773 nucleotide Substances 0.000 claims description 54
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims description 27
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 27
- 102100022545 Bone morphogenetic protein 8B Human genes 0.000 claims description 26
- 101000899368 Homo sapiens Bone morphogenetic protein 8B Proteins 0.000 claims description 26
- 150000001413 amino acids Chemical group 0.000 claims description 26
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 24
- 239000000833 heterodimer Substances 0.000 claims description 19
- 108020004414 DNA Proteins 0.000 claims description 18
- 102000053602 DNA Human genes 0.000 claims description 16
- 125000000539 amino acid group Chemical group 0.000 claims description 13
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 11
- 235000004279 alanine Nutrition 0.000 claims description 11
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 9
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 9
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 6
- 235000003704 aspartic acid Nutrition 0.000 claims description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 6
- 235000013922 glutamic acid Nutrition 0.000 claims description 6
- 239000004220 glutamic acid Substances 0.000 claims description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 claims description 4
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 4
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 3
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 claims 2
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 claims 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 106
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 104
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 46
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 42
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 34
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 32
- 239000000872 buffer Substances 0.000 description 26
- 125000003275 alpha amino acid group Chemical group 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 24
- 229960004198 guanidine Drugs 0.000 description 23
- 239000011780 sodium chloride Substances 0.000 description 23
- 229940024606 amino acid Drugs 0.000 description 22
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 21
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 20
- 241000588724 Escherichia coli Species 0.000 description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 description 17
- 239000004202 carbamide Substances 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 17
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 17
- 210000003000 inclusion body Anatomy 0.000 description 16
- 239000000539 dimer Substances 0.000 description 13
- 239000004475 Arginine Substances 0.000 description 12
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 239000000178 monomer Substances 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 239000008188 pellet Substances 0.000 description 9
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000007943 implant Substances 0.000 description 8
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 108010024636 Glutathione Proteins 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 7
- 229960000583 acetic acid Drugs 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 150000003839 salts Chemical group 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 229920002401 polyacrylamide Polymers 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- MKWKNSIESPFAQN-UHFFFAOYSA-N N-cyclohexyl-2-aminoethanesulfonic acid Chemical compound OS(=O)(=O)CCNC1CCCCC1 MKWKNSIESPFAQN-UHFFFAOYSA-N 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 229960003180 glutathione Drugs 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 241000894007 species Species 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 239000008000 CHES buffer Substances 0.000 description 4
- 108010053070 Glutathione Disulfide Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 4
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- -1 3-(3-chloroaminopropyl)dimethylamino-l-propanesulfonate Chemical compound 0.000 description 3
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 3
- 239000007997 Tricine buffer Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008033 biological extinction Effects 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 230000003196 chaotropic effect Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 239000003398 denaturant Substances 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 239000000710 homodimer Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 238000008940 Alkaline Phosphatase assay kit Methods 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 2
- 101000899388 Homo sapiens Bone morphogenetic protein 5 Proteins 0.000 description 2
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000004067 Osteocalcin Human genes 0.000 description 2
- 108090000573 Osteocalcin Proteins 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 101150114167 ampC gene Proteins 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 101150067309 bmp4 gene Proteins 0.000 description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000022159 cartilage development Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101150061927 BMP2 gene Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 101100174784 Bacillus subtilis (strain 168) ganR gene Proteins 0.000 description 1
- 101150072730 Bmp6 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 1
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101710113100 Membrane-bound alkaline phosphatase Proteins 0.000 description 1
- 101100165560 Mus musculus Bmp7 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 101710151715 Protein 7 Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000702208 Shigella phage SfX Species 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 229940099500 cystamine Drugs 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- WZRZTHMJPHPAMU-UHFFFAOYSA-L disodium;(3e)-3-[(4-amino-3-sulfonatophenyl)-(4-amino-3-sulfophenyl)methylidene]-6-imino-5-methylcyclohexa-1,4-diene-1-sulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(=N)C(C)=CC1=C(C=1C=C(C(N)=CC=1)S([O-])(=O)=O)C1=CC=C(N)C(S(O)(=O)=O)=C1 WZRZTHMJPHPAMU-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 101150043267 lacR gene Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000013289 male long evans rat Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- UYDLBVPAAFVANX-UHFFFAOYSA-N octylphenoxy polyethoxyethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCO)C=C1 UYDLBVPAAFVANX-UHFFFAOYSA-N 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002943 spectrophotometric absorbance Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/163,877 US5399677A (en) | 1993-12-07 | 1993-12-07 | Mutants of bone morphogenetic proteins |
| PCT/US1994/013181 WO1995016034A1 (fr) | 1993-12-07 | 1994-11-15 | Mutants des proteines morphogenetiques osseuses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO962303D0 NO962303D0 (no) | 1996-06-04 |
| NO962303L NO962303L (no) | 1996-06-04 |
| NO317800B1 true NO317800B1 (no) | 2004-12-13 |
Family
ID=22591964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19962303A NO317800B1 (no) | 1993-12-07 | 1996-06-04 | Rekombinante DNA-molekyler som koder for benmorfogene proteiner og rensede sammensetninger og fremgangsmater derav. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US5399677A (fr) |
| EP (1) | EP0733108B1 (fr) |
| JP (1) | JP3704350B2 (fr) |
| KR (1) | KR100361058B1 (fr) |
| AT (1) | ATE200515T1 (fr) |
| AU (1) | AU682238B2 (fr) |
| CA (1) | CA2176943C (fr) |
| DE (1) | DE69427093T2 (fr) |
| DK (1) | DK0733108T3 (fr) |
| ES (1) | ES2157313T3 (fr) |
| FI (1) | FI118428B (fr) |
| GR (1) | GR3035769T3 (fr) |
| NO (1) | NO317800B1 (fr) |
| OA (1) | OA10294A (fr) |
| PT (1) | PT733108E (fr) |
| WO (1) | WO1995016034A1 (fr) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150328A (en) * | 1986-07-01 | 2000-11-21 | Genetics Institute, Inc. | BMP products |
| DE69233022T2 (de) | 1991-11-04 | 2004-02-12 | Genetics Institute, LLC, Cambridge | Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung |
| US20080139474A1 (en) * | 1991-11-04 | 2008-06-12 | David Israel | Recombinant bone morphogenetic protein heterodimers, compositions and methods of use |
| US6291206B1 (en) * | 1993-09-17 | 2001-09-18 | Genetics Institute, Inc. | BMP receptor proteins |
| EP0733109B9 (fr) * | 1993-12-07 | 2006-07-05 | Genetics Institute, LLC | Bmp-12, bmp-13 et compositions de celles-ci pour l'induction de tendons |
| US5942496A (en) | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
| US6551618B2 (en) * | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
| BR9608019A (pt) | 1995-04-19 | 1999-11-30 | Hoechst Japan | Uma nova proteína e um processo para a preparação da mesma' |
| US6040431A (en) * | 1995-06-07 | 2000-03-21 | Stryker Corporation | Single chain analogs of the TGF-β superfamily (morphons) |
| US6048964A (en) * | 1995-12-12 | 2000-04-11 | Stryker Corporation | Compositions and therapeutic methods using morphogenic proteins and stimulatory factors |
| US7026292B1 (en) | 1995-12-12 | 2006-04-11 | Stryker Corporation | Compositions and therapeutic methods using morphogenic proteins and stimulatory factors |
| US5869041A (en) * | 1996-01-12 | 1999-02-09 | The Miriam Hospital | Delivery of bioactive compounds to an organism |
| US7811793B2 (en) * | 1996-12-25 | 2010-10-12 | Biopharma Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh | Process for preparing purified active monomer of bone-derived factor |
| US20040019185A1 (en) * | 1996-12-25 | 2004-01-29 | Hidetoshi Andou | Process for preparing purified active monomer of bone-derived factor |
| ZA9711580B (en) * | 1996-12-25 | 1999-09-23 | Hoechst Marion Roussel Ltd | Process for the production of purified dimeric bone morphogenetic factors. |
| US20020052026A1 (en) * | 1997-10-08 | 2002-05-02 | Steven M. Vicik | Methods of refolding proteins |
| US6391311B1 (en) | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
| US6455283B1 (en) * | 1998-03-17 | 2002-09-24 | Genentech, Inc. | Nucleic acids encoding vascular endothelial cell growth factor-E (VEGF-E) |
| EP2050762A3 (fr) | 1998-03-10 | 2009-07-08 | Genentech, Inc. | Nouvelles polypeptides et acides nucléiques les codant |
| US6677432B1 (en) | 1998-10-07 | 2004-01-13 | Stryker Corporation | Mutations of the C-terminal portion of TGF-β superfamily proteins |
| JP3762222B2 (ja) | 1998-10-07 | 2006-04-05 | ストライカー・コーポレーション | 改変型ＴＧＦ−βスーパーファミリータンパク質 |
| US6846906B1 (en) | 1998-10-07 | 2005-01-25 | Stryker Corporation | Modified proteins of the TGF-β superfamily, including morphogenic proteins |
| US6727224B1 (en) * | 1999-02-01 | 2004-04-27 | Genetics Institute, Llc. | Methods and compositions for healing and repair of articular cartilage |
| DE19906096A1 (de) | 1999-02-13 | 2000-08-17 | Walter Sebald | Protein mit einem Heparin-bindenden Epitop |
| DE19944626A1 (de) * | 1999-09-17 | 2001-03-22 | Knoell Hans Forschung Ev | Verfahren zur Herstellung von dimeren, biologisch aktiven knochenmorphogenetischen Proteinen |
| WO2001028602A1 (fr) | 1999-10-15 | 2001-04-26 | Genetics Institute, Inc. | Formulations a base d'acide hyaluronique aux fins de l'administration de proteines osteogenes |
| US7740841B1 (en) * | 2000-01-28 | 2010-06-22 | Sunnybrook Health Science Center | Therapeutic method for reducing angiogenesis |
| US20030104977A1 (en) * | 2000-03-31 | 2003-06-05 | Ugo Ripamonti | Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors |
| DE10026713A1 (de) * | 2000-05-30 | 2001-12-06 | Walter Sebald | Mutein einer Kette eines Proteins aus der Superfamilie des Wachstumsfaktors TGF-beta |
| US20030082233A1 (en) * | 2000-12-01 | 2003-05-01 | Lyons Karen M. | Method and composition for modulating bone growth |
| ATE393573T1 (de) * | 2001-06-01 | 2008-05-15 | Wyeth Corp | Zusammensetzungen für die systemische verabreichung von sequenzen, die für knochenmorphogenese-proteinen kodieren |
| TWI267378B (en) * | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
| FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| NZ536478A (en) * | 2002-05-17 | 2008-02-29 | Wyeth Corp | Injectable or implantable solid, rod- shaped compositions for intraosseous delivery of osteogenic proteins |
| US20040023322A1 (en) * | 2002-08-01 | 2004-02-05 | Goodheart Clyde R. | Method of producing non-recombinant BMP-2 and use thereof |
| US20060194279A1 (en) * | 2003-07-09 | 2006-08-31 | Fujio Mizukami | Protein-refolding material |
| PT1675608E (pt) * | 2003-09-12 | 2007-05-31 | Etex Corp | Barras sólidas e pastas de fosfato de cálcio injectável para a libertação de proteínas osteogénicas. |
| EP1677735B1 (fr) | 2003-10-17 | 2014-07-23 | Joslin Diabetes Center, Inc. | Methodes et compositions pour moduler la fonction des adipocytes |
| US20070066525A1 (en) * | 2004-02-04 | 2007-03-22 | Lee John C | Compositions and therapeutic methods using morphogenic proteins |
| JP2008501042A (ja) * | 2004-05-19 | 2008-01-17 | ワイス | 免疫グロブリン産生の調節とアトピー性疾患 |
| KR20070057789A (ko) * | 2004-08-05 | 2007-06-07 | 와이어쓰 | 인터루킨-21 수용체 활성의 상쇄 |
| AU2006214384A1 (en) * | 2005-02-14 | 2006-08-24 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of IL-17F in diagnosis and therapy of airway inflammation |
| AU2006214473A1 (en) * | 2005-02-14 | 2006-08-24 | Wyeth | Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor |
| WO2006105359A2 (fr) * | 2005-03-30 | 2006-10-05 | Wyeth | Methodes pour stimuler la pousse des cheveux par administration de proteines bmp |
| GT200600148A (es) | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
| WO2006125868A1 (fr) | 2005-05-27 | 2006-11-30 | Bbs-Bioactive Bone Substitutes Oy | Proteines morphogenetiques d’os contenant un site liant pour l’heparine et dispositifs osteogeniques et produits pharmaceutiques les contenant |
| US7807627B2 (en) | 2005-05-27 | 2010-10-05 | Bbs-Bioactive Bone Substitutes Oy | Bone morphogenetic protein 4 and osteogenic devices and pharmaceutical products containing thereof |
| WO2006125866A1 (fr) | 2005-05-27 | 2006-11-30 | Bbs-Bioactive Bone Substitutes Oy | Proteine morphogenetique d'os 3 et dispositifs osteogeniques et produits pharmaceutiques les contenant |
| WO2006130690A2 (fr) | 2005-06-01 | 2006-12-07 | Joslin Diabetes Center, Inc. | Methodes et compositions permettant d'induire l'adipogenese brune |
| GB0604964D0 (en) * | 2006-03-11 | 2006-04-19 | Renovo Ltd | Protein folding |
| GB0604938D0 (en) | 2006-03-11 | 2006-04-19 | Renovo Ltd | Proteins, nucleic acids and medicaments |
| GB0604966D0 (en) | 2006-03-11 | 2006-04-19 | Renovo Ltd | Medicaments and proteins |
| WO2007139972A2 (fr) * | 2006-05-25 | 2007-12-06 | Wyeth | Expression de la cystéine protéase légumaïne dans des maladies vasculaires et inflammatoires |
| CA2668771C (fr) * | 2006-11-08 | 2016-03-15 | Wyeth | Milieux concus rationnellement pour une culture cellulaire |
| AU2007339280B2 (en) | 2006-12-21 | 2013-12-05 | Stryker Corporation | Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents |
| CL2008000883A1 (es) * | 2007-03-28 | 2008-10-03 | Wyeth6 3 | Metodo de deteccion de compuestos capaces de antagonizar la senalizacion de il-17f/il-17a; compuesto identificado por dicho metodo; uso de una cantidad de un antagonista de senalizacion de il-17f/il-17a, composicion farmaceutica que comprende dicho a |
| TW200902708A (en) * | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
| EP2019117A1 (fr) * | 2007-07-27 | 2009-01-28 | BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH | Procédé de purification optimisé de la protéine recombinante du facteur de croissance |
| US20090042253A1 (en) * | 2007-08-09 | 2009-02-12 | Wyeth | Use of perfusion to enhance production of fed-batch cell culture in bioreactors |
| WO2010051360A1 (fr) * | 2008-10-31 | 2010-05-06 | Wyeth Llc | Purification de protéines acides à l’aide d’une chromatographie sur hydroxyapatite en céramique |
| JP5819733B2 (ja) | 2009-02-12 | 2015-11-24 | ストライカー コーポレイションＳｔｒｙｋｅｒ Ｃｏｒｐｏｒａｔｉｏｎ | 障害および疾患に対する全身治療のためのＴＧＦ−βスーパーファミリーメンバー含有タンパク質の末梢投与 |
| AU2010213591B2 (en) | 2009-02-12 | 2013-11-21 | Stryker Corporation | Compositions and methods for minimally-invasive systemic delivery of proteins including TGF-beta superfamily members |
| US20120148539A1 (en) | 2009-03-24 | 2012-06-14 | Moulay Hicham Alaoui-Ismaili | Methods and Compositions for Tissue Engineering |
| WO2011031856A1 (fr) | 2009-09-09 | 2011-03-17 | Stryker Corporation | Bmp-7 à utiliser dans le traitement de la douleur induite par les lésions et les maladies d'articulation |
| ES2387379T3 (es) | 2009-09-17 | 2012-09-21 | Stryker Corporation | Tampones para controlar el pH de las proteínas morfogenéticas óseas |
| WO2011087768A1 (fr) | 2009-12-22 | 2011-07-21 | Stryker Corporation | Variants de la bmp-7 dotés d'une immunogénicité réduite |
| KR20190005239A (ko) * | 2016-05-31 | 2019-01-15 | 재단법인 목암생명과학연구소 | Tgf-베타 슈퍼패밀리의 ab6 패밀리 디자이너 리간드를 포함하는 간질환 치료용 조성물 및 그의 이용 |
| US11512126B2 (en) | 2016-05-31 | 2022-11-29 | Mogam Institute For Biomedicak Research | AB6 family designer ligands of TGF-β superfamily |
| WO2017209523A1 (fr) * | 2016-05-31 | 2017-12-07 | Mogam Institute For Biomedical Research | Composition comprenant un ligand de conception de la famille ab6 de la super-famille des tgf-bêta pour le traitement de maladies osseuses et cartilagineuses et son utilisation |
| EP4126919A1 (fr) * | 2020-03-24 | 2023-02-08 | Bio-Techne Corporation | Méthodes d'utilisation d'une lignée cellulaire knock-out tgf-bêta et compositions obtenues à partir de celle-ci |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR79124B (fr) * | 1982-12-22 | 1984-10-02 | Genentech Inc | |
| US5106748A (en) * | 1986-07-01 | 1992-04-21 | Genetics Institute, Inc. | Dna sequences encoding 5 proteins |
| ZA874681B (en) * | 1986-07-01 | 1988-04-27 | Genetics Inst | Novel osteoinductive factors |
| US5187076A (en) * | 1986-07-01 | 1993-02-16 | Genetics Institute, Inc. | DNA sequences encoding BMP-6 proteins |
| US5013649A (en) * | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
| GB8927546D0 (en) * | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
| ES2168091T3 (es) * | 1990-05-16 | 2002-06-01 | Genetics Inst | Proteinas de induccion osea y cartilaginosa. |
| WO1992015323A1 (fr) * | 1991-03-11 | 1992-09-17 | Creative Biomolecules, Inc. | Morphogenese induite par des proteines |
| KR100255415B1 (ko) * | 1991-06-25 | 2000-05-01 | 브루스 엠. 에이센 | 비엠피-9 조성물 |
| DE69233022T2 (de) * | 1991-11-04 | 2004-02-12 | Genetics Institute, LLC, Cambridge | Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung |
-
1993
- 1993-12-07 US US08/163,877 patent/US5399677A/en not_active Expired - Lifetime
-
1994
- 1994-11-15 AU AU12093/95A patent/AU682238B2/en not_active Ceased
- 1994-11-15 KR KR1019960703011A patent/KR100361058B1/ko not_active IP Right Cessation
- 1994-11-15 DK DK95903116T patent/DK0733108T3/da active
- 1994-11-15 EP EP95903116A patent/EP0733108B1/fr not_active Expired - Lifetime
- 1994-11-15 JP JP51619695A patent/JP3704350B2/ja not_active Expired - Fee Related
- 1994-11-15 PT PT95903116T patent/PT733108E/pt unknown
- 1994-11-15 ES ES95903116T patent/ES2157313T3/es not_active Expired - Lifetime
- 1994-11-15 CA CA002176943A patent/CA2176943C/fr not_active Expired - Lifetime
- 1994-11-15 WO PCT/US1994/013181 patent/WO1995016034A1/fr active IP Right Grant
- 1994-11-15 AT AT95903116T patent/ATE200515T1/de not_active IP Right Cessation
- 1994-11-15 DE DE69427093T patent/DE69427093T2/de not_active Expired - Lifetime
- 1994-12-21 US US08/360,914 patent/US5756308A/en not_active Expired - Lifetime
-
1996
- 1996-06-04 NO NO19962303A patent/NO317800B1/no unknown
- 1996-06-06 FI FI962349A patent/FI118428B/fi active IP Right Grant
- 1996-06-07 OA OA60839A patent/OA10294A/en unknown
- 1996-10-31 US US08/741,589 patent/US5804416A/en not_active Expired - Lifetime
-
2001
- 2001-04-20 GR GR20010400618T patent/GR3035769T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR100361058B1 (ko) | 2003-04-10 |
| DE69427093D1 (de) | 2001-05-17 |
| JP3704350B2 (ja) | 2005-10-12 |
| AU1209395A (en) | 1995-06-27 |
| FI962349A (fi) | 1996-07-16 |
| ES2157313T3 (es) | 2001-08-16 |
| JPH09506259A (ja) | 1997-06-24 |
| DK0733108T3 (da) | 2001-06-18 |
| AU682238B2 (en) | 1997-09-25 |
| DE69427093T2 (de) | 2001-11-15 |
| GR3035769T3 (en) | 2001-07-31 |
| NO962303D0 (no) | 1996-06-04 |
| ATE200515T1 (de) | 2001-04-15 |
| CA2176943A1 (fr) | 1995-06-15 |
| EP0733108A1 (fr) | 1996-09-25 |
| PT733108E (pt) | 2001-08-30 |
| KR960706558A (ko) | 1996-12-09 |
| US5804416A (en) | 1998-09-08 |
| WO1995016034A1 (fr) | 1995-06-15 |
| US5399677A (en) | 1995-03-21 |
| CA2176943C (fr) | 2007-04-03 |
| OA10294A (en) | 1997-10-07 |
| FI118428B (fi) | 2007-11-15 |
| NO962303L (no) | 1996-06-04 |
| FI962349A0 (fi) | 1996-06-06 |
| EP0733108B1 (fr) | 2001-04-11 |
| US5756308A (en) | 1998-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO317800B1 (no) | Rekombinante DNA-molekyler som koder for benmorfogene proteiner og rensede sammensetninger og fremgangsmater derav. | |
| EP1021528B1 (fr) | Procedes de repliement de proteines au moyen d'agents zwitterioniques a poids moleculaire faible | |
| NO317801B1 (no) | DNA-molekyl, kimaert DNA-molekyl eller vektor som koder for BMP12 eller BMP12-relaterte proteiner, og vertceller, fremgangsmater, proteiner, sammensetninger og anvendelse derav. | |
| NO320119B1 (no) | Benmorfogenetisk protein-11 (BMP-11), DNA-molekyl som koder for dette, samt vektorer og vertceller inneholdende DNA-molekylet og fremgangsmate for fremstilling av BMP-11. | |
| NO300329B1 (no) | Fremgangsmåte for aktivering av rekombinante proteiner | |
| NO317730B1 (no) | Fremgangsmate for fremstilling av dimerisk, biologisk aktivt TGF-beta-lignende protein | |
| NO300067B1 (no) | Fremgangsmåte for å tilveiebringe renset, biologisk aktiv CSF-1 dimer | |
| US20040018595A1 (en) | Production of recombinant bmp-2 | |
| AU690311B2 (en) | Novel process for the production of biologically active dimeric protein | |
| Sharma et al. | Recombinant human epidermal growth factor inclusion body solubilization and refolding at large scale using expanded-bed adsorption chromatography from Escherichia coli | |
| US7947821B2 (en) | Optimized DNA sequences encoding recombinant human bone morphogenetic protein-2 (rhBMP-2), preparation method and the uses thereof | |
| EP0496833A1 (fr) | CONSTRUCTIONS BIOSYNTHETIQUES DE TGF-$g(b) | |
| Andrades et al. | Production of a recombinant human basic fibroblast growth factor with a collagen binding domain | |
| Takamatsu et al. | Expression and purification of biologically active human OSF-1 in Escherichia coli | |
| MXPA00003436A (es) | Metodo para el repliegue de proteinas mediante el uso de agentes zwitterionicos de bajo peso molecular | |
| Yoon et al. | Overproduction of recombinant human bone morphogenetic protein-7 in Chinese hamster ovary cells | |
| CA2574929C (fr) | Proteine morphogenetique osseuse (bmp)-17 et bmp-18 et compositions | |
| CZ2021303A3 (cs) | Termostabilní polypeptid na bázi FGF18 a jeho použití | |
| JPH09262093A (ja) | 蛋白質の活性化方法 |